Glioma Panel 2 near me in Kanchipuram

The Glioma Panel 2 is a focused diagnostic package designed to enable accurate classification, prognostication, and treatment planning for patients with gliomas through integrated molecular and immunohistochemical analysis. The package includes IDH1 and IDH2 mutation testing, which is central to modern glioma classification and provides critical prognostic information. It also evaluates 1p/19q co-deletion status, essential for identifying oligodendrogliomas and guiding therapeutic decisions. In addition, the package incorporates MGMT promoter methylation analysis, a key predictive marker for response to alkylating chemotherapy and overall treatment benefit. ATRX expression is assessed by immunohistochemistry (IHC) to support tumor subtyping and differentiation between astrocytic and oligodendroglial lineages. Together, these complementary molecular and IHC markers provide a comprehensive, clinically actionable profile that aligns with current WHO tumor classification guidelines and supports precision oncology. Getting tested with the Glioma Panel 2 enables clinicians to make informed, evidence-based treatment decisions to ensure that patients receive the most effective and individualized care in the management of glioma.

Note: One representative block of the tumor is required. However, 1-4 representative blocks of tumors are acceptable.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.